Paul Tudor Jones Arcellx, Inc. Transaction History
Tudor Investment Corp Et Al
- $26.8 Billion
- Q3 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Arcellx, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 4,409 shares of ACLX stock, worth $332,394. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,409Holding current value
$332,394% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ACLX
# of Institutions
204Shares Held
44.2MCall Options Held
2.23MPut Options Held
907K-
Paradigm Biocapital Advisors LP New York, NY4MShares$302 Million12.04% of portfolio
-
Perceptive Advisors LLC New York, NY3.89MShares$293 Million8.48% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$282 Million23.89% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$265 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.46MShares$186 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.3B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...